2025 Philly Momentum: In Vivo CAR-T & IIT Pathways Redefining Advanced Therapies
🌟 2025 Philly Momentum: In Vivo CAR-T & IIT Pathways Redefining Advanced Therapies
📅 Date: October 23, 2025
🕞 Time: 3:30 PM – 7:00 PM
📍 Venue: Temple University Center City, 1515 Market Street, Philadelphia
Join us for an exclusive gathering at the 2025 Philly Momentum: In Vivo CAR-T& IIT Pathways Redefining Advanced Therapies where thought leaders, scientists, and industry innovators will explore how In Vivo CAR-T and Investigator-Initiated Trials (IIT) are reshaping the landscape of advanced therapies.
Event Highlights:
CMC-Driven Strategies: Learn how China’s IIT framework is advancing In Vivo CAR-T and CGT development.
Nonclinical Science Trends: Compare China IIT and U.S. IND decision frameworks to uncover regulatory innovation opportunities.
Panel Discussion: Gain insights from leaders across government, investment, scientific, regulatory, and commercial sectors on the emerging U.S.–China Collaboration and business opportunities in drug discovery and development.
It offers a unique opportunity to network with key stakeholders, exchange ideas, and shape the future of global biopharma innovation.
Free ticket and Networking Dinner included.
Agenda
3:30- 4:00PM Registration and light snacks
4:00– 4:10PM — Welcome & Opening Remarks
• Hosted by GB·Partner leadership • Acknowledgement of sponsors and supporting collaborators • Opening remark: Rebecca L Grant Senior Director of Life science & Innovation at Phiadelphia Department of Commerce
4:10– 4:35PM —Keynote -From Bench to Bedside: CMC-Driven Strategies with China IIT to Advance In Vivo CAR-T and CGT Shelley Wu Head of Business development at Porton Advanced 4:35–5:00 PM ---Keynote-- Strategic CAR-T Development: Nonclinical Sicence Trends and China IIT VS U.S. IND Decision FrameworkSean Chen Chief Scientific Officer at Innostar
5:00– 5:50 PM —Panel discussion
Topic: Accelerating Advanced Therapies, with a focus on In Vivo CAR-T and IIT Pathways and U.S.-China Complementarity Investment, Scientific, Regulatory, and Commercial Perspectives
Panelists:
Dong Geng SVP, Head of Early-stage Drug Development at Legned Biotech
Shoubai Chao( Cansinotech COO, they have Venture Fund)
Sara Johnson (Partner at Advantary Capital Partners)
Sean Chen (Innostar CSO）
Shelley Wu (Head of Business Development at Porton advanced)
Interius (TBD)
5:50-6:00 pm Closing Remark
6:00-7:00pm Meal & Networking
Thank you! We hope this event will create a strong momentum and make a meaningful impact for Philly Advanced therapy International.
Best,
GB-Partner Team